Novartis International AG / Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible...
Source : http://www.romandie.com/news/Novartis-Internationa...
Source : http://www.romandie.com/news/Novartis-Internationa...